Navigation Links
Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
Date:3/4/2013

HARTFORD, Conn., March 4, 2013 /PRNewswire/ -- Genomas®, a biomedical company delivering personalized medicine to modern clinical practice, has been awarded clinical laboratory licenses in three of the most populous States. The company's Laboratory of Personalized Health received licenses from the New York Department of Health, the Florida Agency for Health Care Administration, and the California Department of Public Health.

Gualberto Ruano , M.D., Ph.D., President of Genomas and Director of the Laboratory of Personalized Health (LPH) stated: "New York, Florida, and California are among the most demanding States in terms of laboratory technical expertise and business credentialing. Now we are determined to bring our clinical pharmacogenetics services to the people of these States and the entire nation." These key markets herald a national platform for Genomas products in personalized healthcare, medical decision-support and clinical genomic diagnostics.

LPH was certified previously by the Centers for Medicare and Medicaid Services (CMS) under CLIA (Clinical Laboratory Improvement Amendments, and was licensed by the CT Department of Public Health in 2005. In 2012, Genomas had attained credentialing as a Medicare provider and began providing services in Texas and Pennsylvania.

More than 500 clinicians and 5000 patients in Connecticut have already benefited from the Genomas HILOmet PhyzioType® System, which allows personalized management of over 250 drugs to treat mental illness, pain, diabetes, and heart disease. Clinicians access the information through the Personalized Health Portal, which is a secure web-based interface providing data on over 250 different medications. The clinical support extends to 130 neuro-psychiatric drugs (antidepressants, neuroleptics, anticonvulsants, anxiolytics, stimulants, analgesics, hypnotics) and 120 cardio-metabolic drugs (to treat hypertension, diabetes, angina, thrombosis, gastro-esophageal reflux disease, erectile dysfunction, asthma).

In CT, Genomas has established a successful distribution and customer support partnership with Clinical Laboratory Partners (CLP). James Fantus , President and CEO of CLP, and Vice President of Hartford Healthcare Corporation, commented: "It is a great satisfaction to witness a national platform developing through Genomas from Hartford Healthcare partnerships, which include Clinical Laboratory Partners, Hartford Hospital, Institute of Living, and Hospital of Central Connecticut. Genomas is leading Connecticut to national prominence in the clinical practice of personalized medicine."

Please visit www.genomas.com for more information.


'/>"/>
SOURCE Genomas
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. UV Flu Technologies Expands Its International Footprint
2. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
3. Ansell Limited Expands Korean Presence
4. Premier Research Expands Salt Lake City and Phoenix Testing Facilities Adding 50% Capacity
5. Groundbreaking National Program to Reverse Obesity Expands to 50 Locations
6. Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team
7. IntelliCell BioSciences Expands Management Team
8. Questcor Pharmaceuticals Expands Repurchase Program
9. CuraLase Expands with New Franchise in Texas
10. BioNeutral Group Expands The Testing Of Its Ygiene Sterilant Against Anthrax Spores
11. Medtech Expands Nursing Education Opportunities In Florida
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Despite the volatility that continues to ... Today,s pre-market research on ActiveWallSt.com directs the investor community,s focus ... RDUS ), Cerus Corp. (NASDAQ: CERS ), ... Prime Therapeutics Inc. (NASDAQ: FPRX ). Register with ... http://www.activewallst.com/ On Wednesday, shares in ...
(Date:5/25/2016)... Bangkok, Thailand (PRWEB) , ... May 25, 2016 ... ... the participation of a Thai delegation at BIO 2016 in San Francisco. Located ... private sector will be available to answer questions and discuss the Thai biotechnology ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... WEDI, the ... information exchange, today announced that Charles W. Stellar has been named by the WEDI ... CEO since January 2016. As an executive leader with more than 35 years of ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated wealth ... held The Future of San Diego Life Science event at the Estancia La Jolla ... attended the event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):